Diabetes drug eye risk under microscope
NCT ID NCT07602348
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how newer diabetes medications (SGLT2 inhibitors and GLP-1 receptor agonists) affect the eyes of people with type 2 diabetes. Researchers will monitor 40 adults who take metformin and are starting these newer drugs. The goal is to see if these drugs cause any changes in the retina or vision, and how those changes relate to blood vessel health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
2nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens
Athens, Attica, 12462, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug aims to restore vision in Diabetes-Related swelling
- New eye drug aims to restore vision in Diabetes-Related swelling
- Eye scans could spot Diabetes-Related vision damage years early
- Diabetes drug shows promise in fighting advanced cancers
- AI reads eye photos to spot Diabetes-Related vision loss